<SEQUENCE>1
<FILENAME>CNSP_RF1.txt
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
CNS Pharmaceuticals Inc
---------------------------------------
(Name of Issuer)
Common Stock
------------
(Title of Class of Securities)
18978H300
---------
(CUSIP Number)
June 17th, 2024
-----------------
(Date of Event which Requires Filing this Statement)
Check the appropriate box to designate the rule pursuant to which the Schedule
is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 5
SEC 1745 (10-88)
SCHEDULE 13G
CUSIP NO. 18978H300
---------
- ---------------------------------------
1. NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Robert Forster
- -----------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / /.
(b) / /.
- ------------------------------
3. SEC USE ONLY
- ------------------------------
4. CITIZENSHIP OR PLACE OF ORGANIZATION
United States
- -----------------------------
5. SOLE VOTING POWER
0
NUMBER OF
-------- -------------
SHARES 6. SHARED VOTING POWER
BENEFICIALLY 0
OWNED BY
-------- --------------
EACH 7. SOLE DISPOSITIVE POWER
REPORTING 0
PERSON
-------- ---------------
WITH 8. SHARED DISPOSITIVE POWER
0
- -------------------------------- --------
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0
- ------------------------------------------
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES* / /.
- ---------------------------------------
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
0%
- ----------------------------------
12. TYPE OF REPORTING PERSON*
individual
- ------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
Page 2 of 5
STATEMENT ON SCHEDULE 13G
Item 1(a). Name of Issuer:
---------------
CNS Pharmaceuticals Inc
Item 1(b). Address of Issuer's Principal Executive Offices:
------------------------------------------------
2100 West Loop South, Suite 900
Houston, Texas 77027
Item 2(a). Names of Person Filing:
-----------------------
Robert Forster
Item 2(b). Address of Principal Business Office or, if none, Residence:
------------------------------------------------------------
54 Deepdale Dr, Great Neck, NY 11021
Item 2(c). Citizenship:
------------
United States
Item 2(d). Title of Class of Securities:
-----------------------------
Common Stock
Item 2(e). CUSIP Number:
-------------
18978H300
Item 3. If this statement is filed pursuant to Rules 13d-1(b), or
---------------------------------------------------------
13d-2(b), check whether the person filing is a:
-----------------------------------------------
(a) / / Broker or Dealer registered under Section 15 of the Act
(b) / / Bank as defined in section 3(a)(6) of the Act
(c) / / Insurance Company as defined in section 3(a)(19) of the
Act
(d) / / Investment Company registered under section 8 of the
Investment Company Act
(e) / / Investment Advisor registered under section 203 of the
Investment Advisers Act
(f) / / Employee Benefit Plan, Pension Fund which is subject to
the provisions of the Employee Retirement Income
Security Act of 1974 or Endowment Fund;
see Sec.240.13d-1(b)(ii)(F) (Note: See Item 7)
(g) / / Parent Holding Company, in accordance with
Sec.240.13d-1(b)(ii)(G). (Note: See Item 7)
(h) / / Group, in accordance with Sec.240.13d-1(b)(ii)(H).
Page 3 of 5
Item 4. Ownership:
----------
(a) Amount Beneficially Owned: 0 as of 17th June 2024
------
(b) Percent of Class: 0%
-----
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote: 0
------
(ii) shared power to vote or to direct the vote: 0
-----
(iii) sole power to dispose or to direct the disposition of:
0
------
(iv) shared power to dispose or to direct the disposition of:
0
-----
Item 5. Ownership of Five Percent or Less of a Class:
---------------------------------------------
yes
Item 6. Ownership of More than 5 Percent on Behalf of Another Person:
-------------------------------------------------------------
Not Applicable
Item 7. Identification and Classification of the Subsidiary Which
---------------------------------------------------------
Acquired the Security Being Reported on By the Parent Holding
-------------------------------------------------------------
Company:
--------
Not Applicable
Item 8. Identification and Classification of Members of the Group:
----------------------------------------------------------
Not Applicable
Item 9. Notice of Dissolution of Group:
-------------------------------
Not Applicable
Item 10. Certification:
--------------
By signing below, I certify that, to the best of my knowledge
and belief, the securities referred to above were acquired in
the ordinary course of business and were not acquired for the
purpose of and do not have the effect of changing or
influencing the control of the issuer of such securities and
were not acquired in connection with or as a participant in any
transaction having such purposes or effect.
Page 4 of 5
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
Dated: 19th June 2024
-----------------
/s/ Robert Forster
-------------------------
Name: Robert Forster